London, Wendy B.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine

Neuroblastoma Research and TreatmentsGlioma Diagnosis and Treatment

Cited by 1,835

Activating mutations in ALK provide a therapeutic target in neuroblastoma

George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 893

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 858

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease

Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersVirus-based gene therapy research

Cited by 449

A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency

Hacein-Bey-Abina, S., Pai, S.-Y., Gaspar, H. B., Armant, M., Berry, C. C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K. F., et al. (2014) · New England Journal of Medicine

Virus-based gene therapy researchImmunodeficiency and Autoimmune Disorders

Cited by 412

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 318

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Harris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., et al. (2016) · JAMA Oncology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 206

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

Vermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G. P., et al. (2009) · The Lancet Oncology

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 192

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 149

Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study

Liu, K. X., Naranjo, A., Zhang, F. F., DuBois, S. G., Braunstein, S. E., Voss, S. D., Khanna, G., London, W. B., Doski, J. J., Geiger, J. D., et al. (2020) · Journal of Clinical Oncology

Neuroblastoma Research and TreatmentsGlioma Diagnosis and Treatment

Cited by 60

Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system

Stricker, T. P., Morales La Madrid, A., Chlenski, A., Guerrero, L., Salwen, H. R., Gosiengfiao, Y., Perlman, E. J., Furman, W., Bahrami, A., Shohet, J. M., et al. (2014) · Molecular Oncology

Neuroblastoma Research and TreatmentsGene expression and cancer classification

Cited by 36

Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency

Heeney, M. M., Guo, D., De Falco, L., Campagna, D. R., Olbina, G., Kao, P. P.-C., Schmitz-Abe, K., Rahimov, F., Gutschow, P., Westerman, K., et al. (2018) · Blood

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 25

Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.

Shulman, D. S., Klega, K. S., Chen, N., Gohn, E., Henry, D., Choy, E., Cash, T., Schultz, K. A. P., Mascarenhas, L., Bagatell, R., et al. (2024) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 8

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Church, A. J., Corson, L., Kao, P.-C., Imamovic-Tuco, A., Kang, W., Pinto, N. R., Maese, L., Laetsch, T. W., Kim, A., Colace, S., et al. (2021) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 2